BioNTech SE(BNTX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year despite a decrease in COVID-19 vaccine revenues [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - Adjusted non-IFRS net loss for 2025 was EUR 117 million [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in major markets for its COVID vaccine, distributed in over 180 countries [6] - R&D expenses were approximately EUR 2.1 billion, slightly decreased from the prior year, aided by cost savings from active portfolio management [27] - The oncology programs advanced significantly, with over 4,000 patients enrolled across phase 2 and phase 3 studies [6][8] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 due to declining demand in both the U.S. and European markets [30][31] - The U.S. market is expected to be particularly competitive, impacting revenue generation [30] Company Strategy and Development Direction - The company aims to transition to a tumor-centric clinical development program focused on high-incidence cancers, including lung and breast cancer [8] - A new independent company will be established to pursue next-generation mRNA innovations, with BioNTech retaining a minority stake [10][11] - The strategic focus will remain on late-stage oncology assets and combination therapies to maximize value [11][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its strategy and achieve significant clinical data output from 2026 to 2029 [33] - The transition to a new leadership structure is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Other Important Information - The company has established a partnership with BMS to strengthen its oncology programs and de-risk its pumitamig initiatives [6][8] - The company is preparing for multiple late-stage data readouts in 2026, which are expected to inform pivotal trials [8][25] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [37][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [44][46] Question: Why is the leadership transition happening now? - The transition is planned for the end of 2026, coinciding with significant data readouts and the need for industrialization [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech will not contribute cash but will transfer certain rights and mRNA technologies [54][55] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95][96]